Mankind Pharma Limited has informed the Exchange about Investor Presentation
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma reported strong Q4 FY26 results with revenue of Rs 3,443 Cr (11.8% YoY growth) and full-year FY26 revenue of Rs 14,278 Cr (17% YoY growth). Adjusted EBITDA margins improved by 400 bps to 27.1% in Q4, demonstrating operational efficiency gains. The domestic business grew 13% YoY driven by 14.7% growth in cardiac and 11.6% in anti-diabetes segments. Chronic therapy share increased to ~40% in FY26 (up 190 bps), supported by BSV acquisition. Consumer Healthcare segment grew 20% YoY with strong performance from Manforce and Prega News. Exports remained muted at 4% growth due to geo-political headwinds. Net Debt/EBITDA improved to 1.1x from 1.8x in FY24, indicating strong deleveraging. Key brands Telmikind (Rs 783 Cr) and Nurokind (Rs 667 Cr) continued to scale.
Mankind Pharma demonstrated robust margin expansion and deleveraging while maintaining double-digit domestic growth. The focus on chronic therapies and successful integration of BSV acquisition positions the company well for sustainable long-term growth.